Durata Therapeutics (DRTX) – Press Releases
-
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
-
Biothera Pharmaceutical Inc. Announces Board of Directors
-
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
-
FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia
-
Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
-
Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors
-
New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program
-
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Ad
-
Durata Therapeutics Presents Six Dalbavancin Posters at the 24th Annual ECCMID Meeting
-
Durata Therapeutics to Present at Upcoming Investor Conferences
-
Durata Therapeutics Reports First Quarter 2014 Financial Results
-
FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
-
Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results
-
Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014
-
Durata Therapeutics to Present at Upcoming Investor Conferences
-
Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference
Back to DRTX Stock Lookup
